PDA Indolylmaleimides Induce Anti-Tumor Effects in Prostate Carcinoma Cell Lines Through Mitotic Death.
dog
human
mitotic death
mitotic slippage
prostate cancer
whole transcriptome sequencing
Journal
Frontiers in veterinary science
ISSN: 2297-1769
Titre abrégé: Front Vet Sci
Pays: Switzerland
ID NLM: 101666658
Informations de publication
Date de publication:
2020
2020
Historique:
received:
01
05
2020
accepted:
11
12
2020
entrez:
8
2
2021
pubmed:
9
2
2021
medline:
9
2
2021
Statut:
epublish
Résumé
Castrate resistant prostate cancer in men shares several characteristics with canine prostate cancer (PCa). Due to current insufficient therapies, evaluating novel therapeutic agents for late-stage PCa is of considerable interest for both species. PDA indolylmaleimides showed anticancer effects in several neoplastic cell lines. Herein, a comparative characterization of PDA-66 and PDA-377 mediated effects was performed in human and canine PCa cell lines, which is also the first detailed characterization of these agents on cells derived from solid tumors in general. While PDA-377 showed only weak growth inhibition on human PCa cell lines, PDA-66 inhibited proliferation and induced apoptosis in human and canine cell lines with concentrations in the low micromolar range. Morphological characterization and whole transcriptome sequencing revealed that PDA-66 induces mitotic death through its microtubule-depolymerizing ability. PDA-66 appears to be a worthwhile anti-mitotic agent for further evaluation. The similarities in cellular and molecular response observed in the cell lines of both origins form a solid basis for the use of canine PCa
Identifiants
pubmed: 33553272
doi: 10.3389/fvets.2020.558135
pmc: PMC7855975
doi:
Types de publication
Journal Article
Langues
eng
Pagination
558135Informations de copyright
Copyright © 2021 Schille, Nolte, Beck, Jilani, Roolf, Pews-Davtyan, Rolfs, Henze, Beller, Brenig, Junghanss, Schütz and Murua Escobar.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor declared a past co-authorship with one of the authors HM.
Références
Curr Oncol Rep. 2017 May;19(5):32
pubmed: 28361223
Oncogene. 2004 Apr 12;23(16):2825-37
pubmed: 15077146
Q J Nucl Med Mol Imaging. 2015 Sep;59(3):303-16
pubmed: 26200223
Eur J Cancer. 2004 Apr;40(6):858-80
pubmed: 15120042
Animals (Basel). 2020 Jan 05;10(1):
pubmed: 31948021
Vet Surg. 2018 Apr;47(3):367-377
pubmed: 29400404
Front Cell Dev Biol. 2019 Jan 10;6:177
pubmed: 30687704
Lancet. 2016 Jan 2;387(10013):70-82
pubmed: 26074382
Endocr Relat Cancer. 2017 Sep;24(9):T97-T106
pubmed: 28684541
Prostate. 2000 Oct 1;45(2):173-83
pubmed: 11027417
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Prostate. 1986;9(3):247-59
pubmed: 2946029
Nat Rev Mol Cell Biol. 2015 Aug;16(8):473-85
pubmed: 26204159
Anticancer Res. 2015 Apr;35(4):1917-27
pubmed: 25862843
Br J Cancer. 2017 Apr 25;116(9):1186-1194
pubmed: 28334734
Int J Clin Pract. 2011 Nov;65(11):1180-92
pubmed: 21995694
Vet J. 2009 May;180(2):149-62
pubmed: 18786842
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Cancer Invest. 2000;18(8):781-92
pubmed: 11107448
PLoS One. 2020 Mar 13;15(3):e0230272
pubmed: 32168360
Drug Resist Updat. 2016 Jan;24:1-12
pubmed: 26830311
Mediators Inflamm. 2015;2015:146282
pubmed: 26491220
Cancer Res. 1983 Apr;43(4):1809-18
pubmed: 6831420
Bioorg Med Chem. 2010 Sep 15;18(18):6785-95
pubmed: 20708937
Oncotarget. 2017 Jan 10;8(2):3724-3745
pubmed: 27741508
Prostate. 1993;23(3):213-23
pubmed: 7694266
Invest Urol. 1979 Jul;17(1):16-23
pubmed: 447482
Cancer Res. 2015 Jul 1;75(13):2699-707
pubmed: 25939603
BMC Bioinformatics. 2009 May 27;10:161
pubmed: 19473525
Bioorg Med Chem. 2014 Sep 15;22(18):5050-9
pubmed: 24650703
J Biol Methods. 2015;2(1):
pubmed: 26146646
J Immunother Cancer. 2016 Dec 20;4:97
pubmed: 28031824
Biochem Pharmacol. 2013 Mar 15;85(6):763-71
pubmed: 23274302
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Molecules. 2016 May 19;21(5):
pubmed: 27213315
Annu Rev Anim Biosci. 2016;4:199-222
pubmed: 26566160
BMC Cancer. 2014 Feb 06;14:71
pubmed: 24502201
Urology. 1986 Sep;28(3):228-31
pubmed: 3489307
EMBO Rep. 2018 Mar;19(3):
pubmed: 29459486
Nat Rev Mol Cell Biol. 2014 Nov;15(11):736-47
pubmed: 25303117
Transl Res. 2012 Mar;159(3):165-72
pubmed: 22340765
Oncotarget. 2016 Jun 7;7(23):35379-89
pubmed: 27177088
Nucleic Acids Res. 2009 Jan;37(1):1-13
pubmed: 19033363
BMC Cancer. 2008 Aug 15;8:240
pubmed: 18706092
Trends Mol Med. 2011 Jul;17(7):380-8
pubmed: 21439907
Res Vet Sci. 2014 Dec;97(3):568-73
pubmed: 25468798
J Urol. 2005 Feb;173(2):360-72
pubmed: 15643173
Nat Rev Mol Cell Biol. 2011 Jun;12(6):385-92
pubmed: 21527953
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Hered. 2005;96(7):782-5
pubmed: 15994418
PLoS One. 2014 Jun 10;9(6):e98788
pubmed: 24914948
Cell Biol Int. 2014 Jun;38(6):737-46
pubmed: 24677263
Cell Death Differ. 2018 Mar;25(3):486-541
pubmed: 29362479
Cell Death Discov. 2016;2:
pubmed: 27226901
Cytogenet Genome Res. 2011;132(1-2):16-21
pubmed: 20668368
Vet Comp Oncol. 2018 Dec;16(4):450-458
pubmed: 29806232
Org Biomol Chem. 2008 Mar 21;6(6):992-7
pubmed: 18327323